IP Library › Patent Application 18430133
Patent Application
App. No. 18/430,133

PRODUCTION OF CANNABINOID GLYCOSIDE COMPOUNDS IN CELL CULTURE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/430,133
Abstract

The present invention includes systems, methods and compositions for the in vivo bioconversion of water-soluble cannabinoid glycosides in cell cultures.

Claims (29)

1 . A system for glycosylating cannabinoids comprising:

a genetically modified host cell comprising a microorganism expressing a heterologous nucleotide sequence, operably linked to a promotor, encoding at least one heterologous glycosyltransferase that exhibits activity towards one or more cannabinoids and wherein said at least one heterologous glycosyltransferase is selected from the group consisting of: SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID NO. 62, and SEQ ID NO. 64, or a fragment of any of the aforementioned sequences;

one or more cannabinoids;

wherein the one or more cannabinoids are introduced to a cell culture of the genetically modified microorganism.

2 . The system of claim 1 , wherein the genetically modified microorganism is selected from: genetically modified yeast cell, or genetically modified bacterial cell.

3 . The system of claim 2 , wherein said genetically modified yeast cell comprise genetically modified yeast cell is selected from: a genetically modified Pichia pastoris cell, a genetically modified Saccharomyces cerevisiae cell, and genetically modified Kluyveromyces marxianus cell.

4 . The system of claim 2 , wherein said genetically modified bacterial cell comprises a genetically modified Escherichia Coli cell.

5 . The system of claim 1 , wherein said one or more cannabinoids comprises: tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination of the same.

6 . The system of claim 1 , wherein said one or more cannabinoids comprises tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), or a combination of the same.

7 . The system of claim 1 , wherein said one or more cannabinoids comprises: a cannabinoid having between one and four glycosylation moieties.

8 . A system for glycosylating cannabinoids comprising:

a genetically modified host cell comprising a microorganism expressing a heterologous nucleotide sequence, operably linked to a promotor, encoding at least one heterologous glycosyltransferase that exhibits activity towards one or more cannabinoids and wherein said at least one heterologous glycosyltransferase is selected from the group consisting of: SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID NO. 62, and SEQ ID NO. 64, or a heterologous glycosyltransferase having at least 95% sequence identity with SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID NO. 62, or SEQ ID NO. 64;

one or more cannabinoids;

wherein the one or more cannabinoids are introduced to a cell culture of the genetically modified microorganism.

9 . The system of claim 8 , wherein the genetically modified microorganism is selected from: genetically modified yeast cell, or genetically modified bacterial cell.

10 . The system of claim 9 , wherein said genetically modified yeast cell comprise genetically modified yeast cell is selected from: a genetically modified Pichia pastoris cell, a genetically modified Saccharomyces cerevisiae cell, and genetically modified Kluyveromyces marxianus cell.

11 . The system of claim 9 , wherein said genetically modified bacterial cell comprises a genetically modified Escherichia Coli cell.

12 . The system of claim 8 , wherein said one or more cannabinoids comprises: tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination of the same.

13 . The system of claim 8 , wherein said one or more cannabinoids comprises tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), or a combination of the same.

14 . The system of claim 8 , wherein said one or more cannabinoids comprise a cannabinoid having between one and four glycosylation moieties.

15 . A system for glycosylating cannabinoids comprising:

a genetically modified host cell comprising a microorganism expressing a heterologous nucleotide sequence, operably linked to a promotor, encoding at least one heterologous glycosyltransferase that exhibits activity towards one or more cannabinoids and wherein said at least one heterologous glycosyltransferase is selected from the group consisting of: SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID NO. 62, and SEQ ID NO. 64, or a fragment having at least 95% sequence identity with the corresponding fragment of SEQ ID NO. 28, SEQ ID NO. 30, SEQ ID NO. 32, SEQ ID NO. 62, or SEQ ID NO. 64;

one or more cannabinoids;

wherein the one or more cannabinoids are introduced to a cell culture of the genetically modified microorganism.

16 . The system of claim 15 , wherein the genetically modified microorganism is selected from: genetically modified yeast cell, or genetically modified bacterial cell.

17 . The system of claim 16 , wherein said genetically modified yeast cell comprise genetically modified yeast cell is selected from: a genetically modified Pichia pastoris cell, a genetically modified Saccharomyces cerevisiae cell, and genetically modified Kluyveromyces marxianus cell.

18 . The system of claim 16 , wherein said genetically modified bacterial cell comprises a genetically modified Escherichia Coli cell.

19 . The system of claim 15 , wherein said one or more cannabinoids comprises: tetrahydrocannabinol (THC), cannabidiol (CBD), tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), or a combination of the same.

20 . The system of claim 15 , wherein said one or more cannabinoids comprise a cannabinoid having between one and four glycosylation moieties.